This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2004 Jul;3(7):873-5.

Gene profiling and the cyclin-dependent kinase inhibitor flavopiridol: what's in a name?

Steven Grant¹, Paul Dent

Affiliations

PMID: 15252148

Review

Gene profiling and the cyclin-dependent kinase inhibitor flavopiridol: what's in a name?

Steven Grant et al. Mol Cancer Ther. 2004 Jul.

. 2004 Jul;3(7):873-5.

Authors

Steven Grant¹, Paul Dent

Affiliation

¹ Division of Hematology/Oncology, Virginia Commonwealth University/Medical College of Virginia, Richmond, Virginia 23298, USA. stgrant@hsc.vcu.edu

PMID: 15252148

No abstract available

PubMed Disclaimer

Comment on

Transcriptional signature of flavopiridol-induced tumor cell death.
Lü X, Burgan WE, Cerra MA, Chuang EY, Tsai MH, Tofilon PJ, Camphausen K. Lü X, et al. Mol Cancer Ther. 2004 Jul;3(7):861-72. Mol Cancer Ther. 2004. PMID: 15252147

Similar articles

Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases.
Raju U, Ariga H, Koto M, Lu X, Pickett J, Valdecanas D, Mason KA, Milas L. Raju U, et al. Radiother Oncol. 2006 Aug;80(2):185-91. doi: 10.1016/j.radonc.2006.07.027. Epub 2006 Aug 14. Radiother Oncol. 2006. PMID: 16905211
Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol.
de Azevedo WF Jr, Canduri F, da Silveira NJ. de Azevedo WF Jr, et al. Biochem Biophys Res Commun. 2002 Apr 26;293(1):566-71. doi: 10.1016/S0006-291X(02)00266-8. Biochem Biophys Res Commun. 2002. PMID: 12054639
Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ. Carlson BA, et al. Cancer Res. 1996 Jul 1;56(13):2973-8. Cancer Res. 1996. PMID: 8674031
[A novel small molecule cyclin-dependent kinase inhibitor flavopiridol in cancer therapy].
Song Y, Shen J. Song Y, et al. Zhonghua Yi Xue Za Zhi. 2005 Mar 30;85(12):862-4. Zhonghua Yi Xue Za Zhi. 2005. PMID: 15949412 Review. Chinese. No abstract available.
[Flavopiridol, a cyclin-dependent kinase inhibitor].
Lansiaux A, Bailly C. Lansiaux A, et al. Bull Cancer. 2000 Oct;87(10):697-701. Bull Cancer. 2000. PMID: 11084532 Review. French. No abstract available.

See all similar articles

Cited by

Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.
Holkova B, Kmieciak M, Perkins EB, Bose P, Baz RC, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson J, Kang L, Honeycutt C, Tombes MB, Shrader E, Weir-Wiggins C, Wellons M, Sankala H, Hogan KT, Colevas AD, Doyle LA, Figg WD, Coppola D, Roberts JD, Sullivan D, Grant S. Holkova B, et al. Clin Cancer Res. 2014 Nov 15;20(22):5652-62. doi: 10.1158/1078-0432.CCR-14-0805. Epub 2014 Sep 23. Clin Cancer Res. 2014. PMID: 25248382 Free PMC article. Clinical Trial.
Induced growth inhibition, cell cycle arrest and apoptosis in CD133+/CD44+ prostate cancer stem cells by flavopiridol.
Soner BC, Aktug H, Acikgoz E, Duzagac F, Guven U, Ayla S, Cal C, Oktem G. Soner BC, et al. Int J Mol Med. 2014 Nov;34(5):1249-56. doi: 10.3892/ijmm.2014.1930. Epub 2014 Sep 11. Int J Mol Med. 2014. PMID: 25216351 Free PMC article.
Combinatorial antileukemic disruption of oxidative homeostasis and mitochondrial stability by the redox reactive thalidomide 2-(2,4-difluoro-phenyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3(2H)-dione (CPS49) and flavopiridol.
Ge Y, Byun JS, De Luca P, Gueron G, Yabe IM, Sadiq-Ali SG, Figg WD, Quintero J, Haggerty CM, Li QQ, De Siervi A, Gardner K. Ge Y, et al. Mol Pharmacol. 2008 Sep;74(3):872-83. doi: 10.1124/mol.107.040808. Epub 2008 Jun 12. Mol Pharmacol. 2008. PMID: 18556456 Free PMC article.
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.
Bose P, Perkins EB, Honeycut C, Wellons MD, Stefan T, Jacobberger JW, Kontopodis E, Beumer JH, Egorin MJ, Imamura CK, Douglas Figg W Sr, Karp JE, Koc ON, Cooper BW, Luger SM, Colevas AD, Roberts JD, Grant S. Bose P, et al. Cancer Chemother Pharmacol. 2012 Jun;69(6):1657-67. doi: 10.1007/s00280-012-1839-5. Epub 2012 Feb 15. Cancer Chemother Pharmacol. 2012. PMID: 22349810 Free PMC article. Clinical Trial.
Antitumor effects of flavopiridol on human uterine leiomyoma in vitro and in a xenograft model.
Lee HG, Baek JW, Shin SJ, Kwon SH, Cha SD, Park WJ, Chung R, Choi ES, Lee GH, Cho CH. Lee HG, et al. Reprod Sci. 2014 Sep;21(9):1153-60. doi: 10.1177/1933719114525266. Epub 2014 Feb 25. Reprod Sci. 2014. PMID: 24572052 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Other Literature Sources
- The Lens - Patent Citations Database